Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity

Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity

Aim. To elucidate therapeutic effect of metformin-sitaglitin combination on the dynamics of indices of insulin resistance and functional activity of pancreaticbeta-cells, lipid metabolism and body weight in patients with type 2 diabetes mellitus (DM2) and obesity. Materials and methods. The study...

Full description

Bibliographic Details
Main Authors:	Alexander Sergeevich Ametov, Elena Nikolaevna Pakus
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2010-09-01
Series:	Сахарный диабет
Subjects:	type 2 diabetes mellitus obesity metformin sitagliptin
Online Access:	https://www.dia-endojournals.ru/jour/article/view/5490

Similar Items

Influence of novel GPR119 agonist in combination with metformin and sitagliptin on glycemia, body weight and food intake in rats fed a high-fat diet
by: Ivan N. Tyurenkov, et al.
Published: (2019-12-01)

Oxidative stress markers in liver in streptozocin-induced diabetic rats: effects of metformin and sitagliptin
by: Şamil Öztürk, et al.
Published: (2020-12-01)

Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial
by: Mondal Aashish, et al.
Published: (2024-02-01)

Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19
by: Hayder M. Al-Kuraishy, et al.
Published: (2022-11-01)

Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
by: Hayes J, et al.
Published: (2016-07-01)

Development and validation of RP HPLC method for determination of metformin and sitagliptin in bulk and pharmaceutical dosage form
by: Kavitha D., et al.
Published: (2017-04-01)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
by: J Muthukrishnan, et al.
Published: (2012-01-01)

The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes
by: Beljić-Živković Teodora, et al.
Published: (2016-01-01)

Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
by: Hae Kyung Yang, et al.
Published: (2019-06-01)

Comparative study on efficacy of empagliflozin versus sitagliptin, as an add-on therapy to metformin in type 2 diabetic patients
by: Harsh Salankar, et al.
Published: (2024-01-01)

Evaluation of Metformin + Sitagliptin versus Metformin + Glibenclamide on Glycemic Control in Iraqis Type 2 Diabetic Patients
by: Hassan M. Al-Temimi, et al.
Published: (2017-03-01)

Efficacy and safety of metformin and sitagliptin‐based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study
by: Xiangyang Liu, et al.
Published: (2020-11-01)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Pharmacokinetic comparison of sitagliptin and metformin HCl extended-release tablets versus JANUMET® XR in healthy volunteers under fasting and fed conditions
by: Linling Que, et al.
Published: (2023-03-01)

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
by: Masahiro Fukuda, et al.
Published: (2019-03-01)

Safety and Efficacy of Sitagliptin compared with Glimepiride in Patients with Type 2 Diabetes Mellitus inadequately controlled with Metfromin Monotherapy
by: Amjad Abrar, et al.
Published: (2013-07-01)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01)

Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients
by: Young Ki Lee, et al.
Published: (2013-12-01)

Development and validation of a new spectrophotometric method for simultaneous determination of sitagliptin and metformin hydrochloride in tablet pharmaceutical dosage forms using chemometrics technique in comparison with HPLC
by: Maher Ali Almaqtari, et al.
Published: (2023-01-01)

Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes
by: Chunhong Shi, et al.
Published: (2019-04-01)

Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration
by: Won Jun Kim, et al.
Published: (2011-06-01)

Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial
by: Alina Y. Babenko, et al.
Published: (2018-09-01)

Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
by: Soon Ae Kim, et al.
Published: (2011-04-01)

An Effective Delivery System of Sitagliptin Using Optimized Mucoadhesive Nanoparticles
by: Afzal Haq Asif, et al.
Published: (2018-05-01)

Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus
by: A S Ametov, et al.
Published: (2014-08-01)

Effectiveness of Metformin in the Prevention of Gestational Diabetes Mellitus in Obese Pregnant Women
by: Willian Barbosa Sales, et al.
Published: (2018-04-01)

A Case of Janumet Poisoning
by: Arun Bahulikar, et al.
Published: (2017-11-01)

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01)

Prediction of glycosylated hemoglobin level in patients with cardiovascular diseases and type 2 diabetes mellitus with respect to anti-diabetic medication
by: Alisher Ikramov, et al.
Published: (2024-04-01)

ADVANTAGES, SAFETY AND PROSPECTS OF SITAGLIPTIN APPLICATION IN TYPE 2 DIABETES MELLITUS WITH CHRONIC KIDNEY DISEASE
by: I. A. Bonda
Published: (2017-07-01)

Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus
by: Zhang Q, et al.
Published: (2020-12-01)

Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
by: Tirath Patel, et al.
Published: (2023-12-01)

Tip 2 Diyabet Hastalarının Tedavilerine Sitagliptin Eklenmesinin Glisemik Kontrol Üzerine Etkisi
by: Özgür Can, et al.
Published: (2019-09-01)

Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01)

Evaluation of treatment satisfaction, efficacy and safety of dipeptidyl peptidase-4 inhibitors in geriatric patients with type 2 diabetes mellitus: A cross-sectionalcomparative study
by: Harmanjit Singh, et al.
Published: (2018-01-01)

Efficacy and safety of sitagliptin and insulin for latent autoimmune diabetes in adults: A systematic review and meta‐analysis
by: Tong Lin, et al.
Published: (2022-09-01)

Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats
by: Yu-Sheng Liu, et al.
Published: (2015-03-01)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
by: A. V. Simanenkova, et al.
Published: (2021-07-01)

Effects of quercetin, sitagliptin alone or in combination in testicular toxicity induced by doxorubicin in rats
by: Ahmed ZA, et al.
Published: (2019-09-01)

Impact of Treviamet® & Treviamet XR® on quality of life besides glycemic control in type 2 DM patients
by: Asima Khan, et al.
Published: (2023-11-01)